Clinical Data on Arrivo Bio's RABI-767 program to be presented at EPC 2026 Annual Meeting

Presentation highlights ongoing Phase 2 study of pancreatic lipase inhibitor for predicted severe acute pancreatitis The presentation will highlight RABI-767, a small molecule pancreatic lipase inhibitor in development for patients with predicted severe acute pancreatitis (SAP). RABI-767 is designed to inhibit pancreatic lipase activity and interrupt the cascade of fat necrosis associated with tissue injury, organ failure and mortality in SAP, a condition for which no approved therapies currently exist. RABI-767 received Fast Track Designation from the FDA in July 2024. Earlier clinical data presented at the 2025 American Pancreatic Association Annual Meeting, where the abstract was recognized as a "Poster of Distinction", showed RABI-767 was well-tolerated in both healthy adults and patients with predicted SAP, with no adverse safety signals observed and early signs of efficacy seen among participants enrolled in the ongoing Phase 2 study to date. For more about Arrivo Bio and RABI-767, visit www.arrivobio.com. About Arrivo Bio Arrivo is developing first-of-its-kind medicines that target the root cause of hard-to-treat diseases with the goal of achieving meaningful outcomes for patients, allowing them to live longer, healthier lives. Arrivo has two clinical-stage pipeline candidates, Forvisirvat (SP-624) for major depressive disorder and RABI-767 for predicted severe acute pancreatitis. Arrivo is based in Morrisville, N.C., on the edge of Research Triangle Park. For more information, visit www.arrivobio.com. Contacts: Media: Maggie Turano Account Director, ICR Healthcare maggie.turano@icrhealthcare.com